New mRNA flu vaccine shows promise in first human trial

NCT ID NCT06125691

Completed ⭐️ VACCINE ⭐️ Sponsor: Arcturus Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new type of flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger and longer-lasting protection. The study involved 139 healthy adults aged 18-49 and 65-85, who received either the experimental vaccine or a licensed flu shot. Researchers monitored safety, side effects, and immune responses to determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Self-amplifying mRNA seasonal influenza vaccine (ARCT-2138)
What this could lead to: If successful, this could lead to a more effective and longer-lasting seasonal flu vaccine using self-amplifying mRNA technology.
What could go wrong: This is an early Phase 1 trial with only 139 participants, so safety and immune response are still being tested. It may not work as well as existing vaccines or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN

Contacts and locations

Show contact details

Locations

Emeritus Research Camberwell

Melbourne, Victoria, 3124, Australia
Nucleus Network Brisbane Clinic

Brisbane, Queensland, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.